Cochrane · systematic review · CD010290
Gonadotrophins for ovulation induction in women with polycystic ovary syndrome
Weiss, NS, Kostova, E, Nahuis, M, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
15
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 40%Low 6 · 40%Moderate 3 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRecombinant follicle stimulating hormone versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome
Population: women with polycystic ovarian syndrome (PCOS) undergoing ovulation induction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth rate per woman Recombinant follicle stimulating hormone vs urinary‐derived gonadotrophins | RR 1.21 [0.83, 1.78] | 5 studies · 505 participants | Low Downgraded: imprecision, inconsistency |
Incidence of multiple pregnancy (per woman) Recombinant follicle stimulating hormone vs urinary‐derived gonadotrophins | RR 0.86 [0.46, 1.61] | 8 studies · 1368 participants | Low Downgraded: imprecision, inconsistency |
Clinical pregnancy rate per woman Recombinant follicle stimulating hormone vs urinary‐derived gonadotrophins | RR 1.05 [0.88, 1.27] | 8 studies · 1330 participants | Low Downgraded: imprecision, inconsistency |
Miscarriage rate per woman Recombinant follicle stimulating hormone vs urinary‐derived gonadotrophins | RR 1.2 [0.71, 2.04] | 7 studies · 970 participants | Low Downgraded: imprecision, inconsistency |
Incidence of OHSS per woman Recombinant follicle stimulating hormone vs urinary‐derived gonadotrophins | RR 1.48 [0.82, 2.65] | 10 studies · 1565 participants | Very low Downgraded: imprecision, inconsistency |
Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin versus urinary follicle stimulating hormone for ovulation induction in women with polycystic ovarian syndrome
Population: women with polycystic ovarian syndrome (PCOS) undergoing ovulation induction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth rate per woman Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin vs urinary follicle stimulating hormone | RR 1.28 [0.65, 2.52] | 3 studies · 138 participants | Very low Downgraded: imprecision, inconsistency |
Incidence of multiple pregnancy (per woman) Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin vs urinary follicle stimulating hormone | RR 2.13 [0.51, 8.91] | 4 studies · 161 participants | Very low Downgraded: imprecision, inconsistency |
Clinical pregnancy rate per woman Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin vs urinary follicle stimulating hormone | RR 1.31 [0.66, 2.59] | 3 studies · 102 participants | Very low Downgraded: imprecision, inconsistency |
Miscarriage rate per woman Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin vs urinary follicle stimulating hormone | RR 0.33 [0.06, 1.97] | 2 studies · 98 participants | Very low Downgraded: imprecision, inconsistency |
Incidence of OHSS per woman Human menopausal gonadotrophin or highly purified human menopausal gonadotrophin vs urinary follicle stimulating hormone | RR 7.07 [0.42, 117.81] | 2 studies · 53 participants | Very low Downgraded: imprecision, inconsistency |
Gonadotrophins compared to continued clomiphene citrate for ovulation induction
Population: anovulatory women with clomiphene citrate‐failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth rate per woman Gonadotrophins vs continued clomiphene citrate | RR 1.24 [1.05, 1.46] | 1 study · 661 participants | Moderate Downgraded: risk of bias |
Incidence of multiple pregnancy per woman Gonadotrophins vs continued clomiphene citrate | RR 0.89 [0.33, 2.4] | 1 study · 661 participants | Moderate Downgraded: risk of bias |
Clinical pregnancy rate per woman Gonadotrophins vs continued clomiphene citrate | RR 1.31 [1.13, 1.52] | 1 study · 661 participants | Moderate Downgraded: risk of bias |
Miscarriages per woman Gonadotrophins vs continued clomiphene citrate | RR 2.23 [1.11, 4.47] | 1 study · 661 participants | Low Downgraded: risk of bias |
Incidence of OHSS per woman Gonadotrophins vs continued clomiphene citrate | no estimate extracted | 1 study · 661 participants | Low Downgraded: risk of bias |
Recombinant FSH versus urinary‐derived gonadotrophins for ovulation induction in women with polycystic ovarian syndrome
Population: women with polycystic ovarian syndrome undergoing ovulation induction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth rate per woman Recombinant FSH vs urinary‐derived gonadotrophins | OR 1.26 [0.8, 1.99] | 5 studies · 505 participants | Low Downgraded: imprecision, inconsistency |
Incidence of OHSS per woman Recombinant FSH vs urinary‐derived gonadotrophins | OR 1.52 [0.81, 2.84] | 10 studies · 1565 participants | Very low Downgraded: imprecision, inconsistency |
Clinical pregnancy rate per woman Recombinant FSH vs urinary‐derived gonadotrophins | OR 1.08 [0.83, 1.39] | 8 studies · 1330 participants | Low Downgraded: imprecision, inconsistency |
Miscarriage rate per woman Recombinant FSH vs urinary‐derived gonadotrophins | OR 1.22 [0.69, 2.15] | 7 studies · 970 participants | Low Downgraded: imprecision, inconsistency |
Incidence of multiple pregnancy (per woman) Recombinant FSH vs urinary‐derived gonadotrophins | OR 0.86 [0.44, 1.65] | 8 studies · 1368 participants | Low Downgraded: imprecision, inconsistency |
HMG or HP‐HMG versus uFSH for ovulation induction in women with polycystic ovarian syndrome
Population: women with polycystic ovarian syndrome undergoing ovulation induction
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth rate per woman HMG or HP‐HMG vs uFSH | OR 1.36 [0.58, 3.18] | 3 studies · 138 participants | Low Downgraded: imprecision, inconsistency |
Incidence of OHSS per woman HMG or HP‐HMG vs uFSH | OR 9.95 [0.47, 210] | 2 studies · 53 participants | Very low Downgraded: imprecision, inconsistency |
Clinical pregnancy rate per woman HMG or HP‐HMG vs uFSH | OR 1.44 [0.55, 3.77] | 3 studies · 102 participants | Low Downgraded: imprecision, inconsistency |
Miscarriage rate per woman HMG or HP‐HMG vs uFSH | OR 0.3 [0.04, 2.05] | 2 studies · 98 participants | Low Downgraded: imprecision, inconsistency |
Incidence of multiple pregnancy (per woman) HMG or HP‐HMG vs uFSH | OR 2.26 [0.47, 10.95] | 4 studies · 161 participants | Low Downgraded: imprecision, inconsistency |